Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Cancer

Cancer

Epidermal growth factor receptor (EGFR); insulin-like growth factor-1 receptor (IGF1R; CD221)

Mouse studies suggest a bispecific antibody against EGFR and IGF1R could help treat cancer. The antibody has a Fab portion that binds to and inhibits EGFR and IGF1R and an Fc portion that enhances antibody-dependent cytotoxicity. In multiple mouse xenograft models of cancer, the bispecific antibody decreased tumor growth and increased survival compared with vehicle or monospecific antibodies against EGFR or IGF1R. Next steps include further optimizing the antibody and performing affinity maturation on the IGF1R-binding arm.

SciBX 7(25); doi:10.1038/scibx.2014.731
Published online June 26, 2014

Patent and licensing status undisclosed

Schanzer, J.M. et al. J. Biol. Chem.; published online May 19, 2014;
doi:10.1074/jbc.M113.528109
Contact: Juergen M. Schanzer, Roche Diagnostics GmbH, Penzberg, Germany
e-mail:

juergen_michael.schanzer@roche.com